
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549**

FORM 8-K

CURRENT REPORT

**Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934**

Date of report: October 16, 2017
(Date of earliest event reported)

IDEX CORPORATION

(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction
of incorporation)

1-10235
(Commission File Number)

36-3555336
(IRS Employer
Identification No.)

1925 W. Field Court
Lake Forest, Illinois 60045
(Address of principal executive offices, including zip code)
(847) 498-7070
(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-
-

Item 2.02 – Results of Operations and Financial Condition.

On October 16, 2017, IDEX Corporation (the “Company”) issued a press release announcing financial results for the period ended September 30, 2017.

A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information in this Current Report furnished pursuant to Item 2.02 shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. This information shall not be incorporated by reference into any registration statement pursuant to the Securities Act of 1933, as amended.

Item 7.01 - Regulation FD Disclosure.

Q3 2017 Presentation Slides

Presentation slides discussing IDEX Corporation’s quarterly operating results are attached to this Current Report on Form 8-K as Exhibit 99.2 and are incorporated herein by reference.

The Securities and Exchange Commission encourages companies to disclose forward-looking information so that investors can better understand the future prospects of a company and make informed investment decisions. This Current Report and the Exhibits hereto may contain “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. These statements may relate to, among other things, capital expenditures, acquisitions, cost reductions, cash flow, revenues, earnings, market conditions, global economies and operating improvements, and are indicated by words or phrases such as “anticipate,” “estimate,” “plans,” “expects,” “projects,” “forecasts,” “should,” “could,” “will,” “management believes,” “the company believes,” “the company intends,” and similar words or phrases. These statements are subject to inherent uncertainties and risks that could cause actual results to differ materially from those anticipated at the date of this Current Report. The risks and uncertainties include, but are not limited to, the following: economic and political consequences resulting from terrorist attacks and wars; levels of industrial activity and economic conditions in the U.S. and other countries around the world; pricing pressures and other competitive factors, and levels of capital spending in certain industries - all of which could have a material impact on order rates and IDEX’s results, particularly in light of the low levels of order backlogs it typically maintains; its ability to make acquisitions and to integrate and operate acquired businesses on a profitable basis; the relationship of the U.S. dollar to other currencies and its impact on pricing and cost competitiveness; political and economic conditions in foreign countries in which the company operates; interest rates; capacity utilization and the effect this has on costs; labor markets; market conditions and material costs; and developments with respect to contingencies, such as litigation and environmental matters. Additional factors that could cause actual results to differ materially from those reflected in the forward-looking statements include, but are not limited to, the risks discussed in the “Risk Factors” section included in the IDEX’s most recent annual report on Form 10-K filed with the Securities and Exchange Commission (SEC) and the other risks discussed in the company’s filings with the SEC. The forward-looking statements included in this Current Report and the Exhibits hereto are only made as of the date of this Current Report, and management undertakes no obligation to publicly update them to reflect subsequent events or circumstances, except as may be required by law. Investors are cautioned not to rely unduly on forward-looking statements when evaluating the information presented herein.

The information in this Current Report furnished pursuant to Items 7.01 and 9.01 shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. This information shall not be incorporated by reference into any registration statement pursuant to the Securities Act of 1933, as amended. The furnishing of the information in this Current Report is not intended to, and does not, constitute a representation that such furnishing is required by Regulation FD or that the information this Current Report contains is material investor information that is not otherwise publicly available.

Item 9.01 – Financial Statements and Exhibits.

(d) Exhibits

- 99.1 Press release dated October 16, 2017 announcing IDEX Corporation’s quarterly operating results.
- 99.2 Presentation slides of IDEX Corporation’s quarterly operating results

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

IDEX CORPORATION

By: /s/ WILLIAM K. GROGAN

William K. Grogan

Senior Vice President and Chief Financial Officer

October 16, 2017

EXHIBIT INDEX

Exhibit Number	Description
---------------------------	--------------------

99.1

[Press release dated October 16, 2017](#)

99.2

[Presentation slides of IDEX Corporation's quarterly operating results](#)



For further information: **TRADED: NYSE (IEX)**

Investor Contact:

William K. Grogan
Senior Vice President and Chief Financial Officer
(847) 498-7070

MONDAY, OCTOBER 16, 2017

**IDEX REPORTS RECORD THIRD QUARTER ORDERS, SALES AND EPS;
RAISES FULL YEAR EPS GUIDANCE**

LAKE FOREST, IL, OCTOBER 16 - IDEX Corporation (NYSE: IEX) today announced its financial results for the three month period ended September 30, 2017.

Third Quarter 2017 Highlights

- Orders were up 8 percent overall and 7 percent organically
- Sales were up 8 percent overall and 7 percent organically
- Operating margin was 22.0 percent
- EPS was \$1.08, up 17 cents, or 19 percent

Third Quarter 2017

Orders of \$573.8 million were up 8 percent (+7 percent organic and +1 percent foreign currency translation) compared with the prior year period.

Sales of \$574.5 million were up 8 percent (+7 percent organic and +1 percent foreign currency translation) compared with the prior year period.

Gross margin of 44.9 percent was up 140 basis points from the prior year period. Excluding \$4.6 million of pre-tax fair value inventory step-up charges from the prior year period, gross margin would have been up 50 basis points primarily due to volume leverage.

Operating income of \$126.5 million resulted in an operating margin of 22.0 percent, up 130 basis points from the prior year operating margin and 90 basis points from the prior year adjusted operating margin. Excluding the \$4.6 million fair value step-up charges from the prior year results, operating margin would have been up 10 basis points. Operating income drove EBITDA of \$146.1 million which was 25 percent of sales and covered interest expense by more than 13 times.

Net income was \$83.8 million which resulted in EPS of \$1.08, up 17 cents, or 19 percent, from the prior year period. Excluding the net loss on divestitures from the prior year period, EPS was up 16 cents, or 17 percent from adjusted prior year EPS.

Cash from operations for the third quarter of \$124.0 million led to free cash flow of \$115.5 million, which converted at 138 percent of net income.

The Company repurchased 116 thousand shares of common stock for \$13.8 million in the third quarter of 2017.

“Solid execution, coupled with increasing demand, delivered another strong quarter for IDEX. Third quarter organic orders and sales both grew 7 percent, which drove operating margin of 22.0 percent. HST and FMT continued to lead the way with 10 percent and 7 percent organic revenue growth, respectively. This growth resulted in EPS of \$1.08 which was up 16 cents, or 17 percent, from the adjusted prior year period. Free cash flow was very strong with a conversion rate at 138 percent of net income.

I am pleased with the solid organic growth rates we have achieved this year. Consistent with our capital deployment strategy, our number one priority is to fully fund long-term organic growth opportunities. Our commitment to segmenting our businesses and funding our best organic initiatives is helping to deliver on our goal of outperforming our underlying markets. Looking ahead, we will continue to fund these opportunities as an integral part of our capital deployment objectives which include pursuing strategic M&A, funding our dividend and being opportunistic in repurchasing our shares.

Based on our third quarter results and strength in orders across all three segments, we are raising full year 2017 adjusted EPS guidance to \$4.25 to \$4.27, with fourth quarter EPS of \$1.06 to \$1.08. We also reaffirm full year 2017 organic revenue growth of 5 percent, with 6 percent organic growth expected in the fourth quarter.”

Andrew K. Silvernail
Chairman and Chief Executive Officer

Third Quarter 2017 Segment Highlights

Fluid & Metering Technologies

- Sales of \$221.0 million reflected a 6 percent increase compared to the third quarter of 2016 (+7 percent organic, -2 percent divestitures and +1 percent foreign currency translation).
- Operating income of \$62.0 million resulted in an operating margin of 28.1 percent, a 130 basis point increase compared to the prior year period operating margin primarily due to higher volume, cost savings from prior year restructuring initiatives and lower amortization.
- EBITDA of \$68.0 million resulted in an EBITDA margin of 30.8 percent, a 60 basis point increase compared to the prior year period EBITDA margin.

Health & Science Technologies

- Sales of \$207.1 million reflected a 13 percent increase compared to the third quarter of 2016 (+10 percent organic and +3 percent acquisition/divestitures).
- Operating income of \$46.1 million resulted in an operating margin of 22.2 percent, a 190 basis point increase compared to the prior year period operating margin primarily due to higher volume and the inclusion of a fair value inventory step-up charge in the prior year period.
- EBITDA of \$58.2 million resulted in an EBITDA margin of 28.1 percent, a 150 basis point increase compared to the prior year period EBITDA margin.

Fire & Safety/Diversified Products

- Sales of \$146.6 million reflected a 6 percent increase compared to the third quarter of 2016 (+4 percent organic and +2 percent foreign currency translation).
- Operating income of \$36.2 million resulted in an operating margin of 24.7 percent, a 130 basis point increase compared to the prior year period operating margin primarily due to higher volume and the inclusion of a fair value inventory step-up charge in the prior year period.
- EBITDA of \$38.9 million resulted in an EBITDA margin of 26.5 percent, a 40 basis point increase compared to the prior year period EBITDA margin.

For the third quarter of 2017, Fluid & Metering Technologies contributed 38 percent of sales, 43 percent of operating income and 41 percent of EBITDA; Health & Science Technologies accounted for 36 percent of

sales, 32 percent of operating income and 35 percent of EBITDA; and Fire & Safety/Diversified Products represented 26 percent of sales, 25 percent of operating income and 24 percent of EBITDA.

Non-U.S. GAAP Measures of Financial Performance

The Company supplements certain U.S. GAAP financial performance metrics with non-U.S. GAAP financial performance metrics in order to provide investors with better insight and increased transparency while also allowing for a more comprehensive understanding of the financial information used by management in its decision making. Reconciliations of non-U.S. GAAP financial performance metrics to their most comparable U.S. GAAP financial performance metrics are defined and presented below and should not be considered a substitute for, nor superior to, the financial data prepared in accordance with U.S. GAAP. There were no adjustments to U.S. GAAP financial performance metrics other than the items noted below.

- Organic orders and sales are calculated according to U.S. GAAP excluding amounts from acquired or divested businesses during the first twelve months of ownership or divestiture and the impact of foreign currency translation.
- Adjusted operating income is calculated as operating income plus restructuring expenses plus or minus the net loss or gain on sale of businesses.
- Adjusted operating margin is calculated as adjusted operating income divided by net sales.
- Adjusted net income is calculated as net income plus restructuring expenses plus or minus the net loss or gain on sale of businesses, net of the statutory tax expense or benefit.
- EBITDA is calculated as net income plus interest expense plus provision for income taxes plus depreciation and amortization. We reconciled EBITDA to net income on a consolidated basis as we do not allocate consolidated interest expense or consolidated provision for income taxes to our segments.
- Adjusted EBITDA is calculated as EBITDA plus restructuring expenses plus or minus the net loss or gain on sale of businesses.
- Free cash flow is calculated as cash flow from operating activities less capital expenditures.

Table 1: Reconciliations of the Change in Net Sales to Net Organic Sales

	Quarter Ended				Nine Months Ended			
	September 30, 2017				September 30, 2017			
	FMT	HST	FSDP	IDEX	FMT	HST	FSDP	IDEX
Change in net sales	6%	13%	6%	8%	3%	10%	12%	8%
- Net impact from acquisitions/divestitures	(2%)	3%	0%	0%	(2%)	4%	12%	4%
- Impact from FX	1%	0%	2%	1%	0%	(1%)	(1%)	(1%)
Change in net organic sales	<u>7%</u>	<u>10%</u>	<u>4%</u>	<u>7%</u>	<u>5%</u>	<u>7%</u>	<u>1%</u>	<u>5%</u>

Table 2: Reconciliations of Reported-to-Adjusted Operating Income and Margin (dollars in thousands)

	Quarter Ended September 30,									
	2017					2016 ^(e)				
	FMT	HST	FSDP	Corporate	IDEX	FMT	HST	FSDP	Corporate	IDEX
Reported operating income (loss)	\$ 61,988	\$ 46,073	\$ 36,199	\$ (17,756)	\$ 126,504	\$ 55,907	\$ 37,195	\$ 32,492	\$ (15,886)	\$ 109,708
+Loss (gain) on sale of businesses - net	-	-	-	-	-	-	-	-	2,067	2,067
Adjusted operating income (loss)	\$ 61,988	\$ 46,073	\$ 36,199	\$ (17,756)	\$ 126,504	\$ 55,907	\$ 37,195	\$ 32,492	\$ (13,819)	\$ 111,775
Net sales (eliminations)	\$ 220,953	\$ 207,127	\$ 146,599	\$ (189)	\$ 574,490	\$ 208,335	\$ 183,564	\$ 138,767	\$ (310)	\$ 530,356
Operating margin	28.1 %	22.2 %	24.7 %	n/m	22.0 %	26.8 %	20.3 %	23.4 %	n/m	20.7 %
Adjusted operating margin	28.1 %	22.2 %	24.7 %	n/m	22.0 %	26.8 %	20.3 %	23.4 %	n/m	21.1 %

	Nine Months Ended September 30,									
	2017					2016 ^(e)				
	FMT	HST	FSDP	Corporate	IDEX	FMT	HST	FSDP	Corporate	IDEX
Reported operating income (loss)	\$ 179,830	\$ 134,605	\$ 106,022	\$ (53,149)	\$ 367,308	\$ 161,782	\$ 118,985	\$ 92,566	\$ (46,457)	\$ 326,876
+Restructuring expenses	1,566	3,028	73	130	4,797	-	-	-	-	-
+Loss (gain) on sale of businesses - net	-	-	-	-	-	-	-	-	2,067	2,067
Adjusted operating income (loss)	\$ 181,396	\$ 137,633	\$ 106,095	\$ (53,019)	\$ 372,105	\$ 161,782	\$ 118,985	\$ 92,566	\$ (44,390)	\$ 328,943
Net sales (eliminations)	\$ 658,905	\$ 611,215	\$ 432,029	\$ (741)	\$ 1,701,408	\$ 641,988	\$ 556,475	\$ 384,996	\$ (835)	\$ 1,582,624
Operating margin	27.3 %	22.0 %	24.5 %	n/m	21.6 %	25.2 %	21.4 %	24.0 %	n/m	20.7 %
Adjusted operating margin	27.5 %	22.5 %	24.6 %	n/m	21.9 %	25.2 %	21.4 %	24.0 %	n/m	20.8 %

Table 3: Reconciliations of Reported-to-Adjusted Net Income and EPS (in thousands, except EPS)

	Quarter		Nine Months	
	Ended September 30,		Ended September 30,	
	2017	2016	2017	2016
Reported net income	\$ 83,768	\$ 69,873	\$ 243,511	\$ 213,762
+Restructuring expenses	-	-	4,797	-
+Tax impact on restructuring expenses	-	-	(1,529)	-
+Loss (gain) on sale of businesses - net	-	2,067	-	2,067
+Tax impact on loss (gain) on sale of businesses - net	-	(1,467)	-	(1,467)
Adjusted net income	\$ 83,768	\$ 70,473	\$ 246,779	\$ 214,362
Reported EPS	\$ 1.08	\$ 0.91	\$ 3.15	\$ 2.78
+Restructuring expenses	-	-	0.06	-
+Tax impact on restructuring expenses	-	-	(0.02)	-
+Loss (gain) on sale of businesses - net	-	0.03	-	0.03
+Tax impact on loss (gain) on sale of businesses - net	-	(0.02)	-	(0.02)
Adjusted EPS	\$ 1.08	\$ 0.92	\$ 3.19	\$ 2.79
Diluted weighted average shares	77,523	76,880	77,246	76,742

Table 4: Reconciliations of EBITDA to Net Income (dollars in thousands)

	Quarter Ended September 30,									
	2017					2016 ^(a)				
	FMT	HST	FSDP	Corporate	INDEX	FMT	HST	FSDP	Corporate	INDEX
Operating income (loss)	\$ 61,988	\$ 46,073	\$ 36,199	\$ (17,756)	\$ 126,504	\$ 55,907	\$ 37,195	\$ 32,492	\$ (15,886)	\$ 109,708
- Other (income) expense - net	230	(970)	1,044	1,349	1,653	171	(384)	(195)	(1,105)	(1,513)
+ Depreciation and amortization	6,192	11,189	3,709	190	21,280	7,168	11,163	3,584	277	22,192
EBITDA	67,950	58,232	38,864	(18,915)	146,131	62,904	48,742	36,271	(14,504)	133,413
- Interest expense					11,064					11,913
- Provision for income taxes					30,019					29,435
- Depreciation and amortization					21,280					22,192
Net income					\$ 83,768					\$ 69,873
Net sales (eliminations)	\$ 220,953	\$ 207,127	\$ 146,599	\$ (189)	\$ 574,490	\$ 208,335	\$ 183,564	\$ 138,767	\$ (310)	\$ 530,356
Operating margin	28.1 %	22.2 %	24.7 %	n/m	22.0 %	26.8 %	20.3 %	23.4 %	n/m	20.7 %
EBITDA margin	30.8 %	28.1 %	26.5 %	n/m	25.4 %	30.2 %	26.6 %	26.1 %	n/m	25.2 %

	Nine Months Ended September 30,									
	2017					2016 ^(a)				
	FMT	HST	FSDP	Corporate	INDEX	FMT	HST	FSDP	Corporate	INDEX
Operating income (loss)	\$ 179,830	\$ 134,605	\$ 106,022	\$ (53,149)	\$ 367,308	\$ 161,782	\$ 118,985	\$ 92,566	\$ (46,457)	\$ 326,876
- Other (income) expense - net	707	97	1,663	(750)	1,717	566	(1,548)	(485)	(1,029)	(2,496)
+ Depreciation and amortization	17,823	34,447	10,938	598	63,806	22,011	33,044	8,316	953	64,324
EBITDA	196,946	168,955	115,297	(51,801)	429,397	183,227	153,577	101,367	(44,475)	393,696
- Interest expense					33,920					33,607
- Provision for income taxes					88,160					82,003
- Depreciation and amortization					63,806					64,324
Net income					\$ 243,511					\$ 213,762
Net sales (eliminations)	\$ 658,905	\$ 611,215	\$ 432,029	\$ (741)	\$ 1,701,408	\$ 641,988	\$ 556,475	\$ 384,996	\$ (835)	\$ 1,582,624
Operating margin	27.3 %	22.0 %	24.5 %	n/m	21.6 %	25.2 %	21.4 %	24.0 %	n/m	20.7 %
EBITDA margin	29.9 %	27.6 %	26.7 %	n/m	25.2 %	28.5 %	27.6 %	26.3 %	n/m	24.9 %

Table 5: Reconciliations of EBITDA to Adjusted EBITDA (dollars in thousands)

	Quarter Ended September 30,									
	2017					2016				
	FMT	HST	FSDP	Corporate	INDEX	FMT	HST	FSDP	Corporate	INDEX
EBITDA	\$ 67,950	\$ 58,232	\$ 38,864	\$ (18,915)	\$ 146,131	\$ 62,904	\$ 48,742	\$ 36,271	\$ (14,504)	\$ 133,413
+Loss (gain) on sale of businesses - net	-	-	-	-	-	-	-	-	2,067	2,067
Adjusted EBITDA	\$ 67,950	\$ 58,232	\$ 38,864	\$ (18,915)	\$ 146,131	\$ 62,904	\$ 48,742	\$ 36,271	\$ (12,437)	\$ 135,480
Adjusted EBITDA margin	30.8 %	28.1 %	26.5 %	n/m	25.4 %	30.2 %	26.6 %	26.1 %	n/m	25.5 %

	Nine Months Ended September 30,									
	2017					2016				
	FMT	HST	FSDP	Corporate	INDEX	FMT	HST	FSDP	Corporate	INDEX
EBITDA	\$ 196,946	\$ 168,955	\$ 115,297	\$ (51,801)	\$ 429,397	\$ 183,227	\$ 153,577	\$ 101,367	\$ (44,475)	\$ 393,696
+Restructuring expenses	1,566	3,028	73	130	4,797	-	-	-	-	-
+Loss (gain) on sale of businesses - net	-	-	-	-	-	-	-	-	2,067	2,067
Adjusted EBITDA	\$ 198,512	\$ 171,983	\$ 115,370	\$ (51,671)	\$ 434,194	\$ 183,227	\$ 153,577	\$ 101,367	\$ (42,408)	\$ 395,763
Adjusted EBITDA margin	30.1 %	28.1 %	26.7 %	n/m	25.5 %	28.5 %	27.6 %	26.3 %	n/m	25.0 %

Table 6: Reconciliations of Free Cash Flow (in thousands)

	Quarter Ended					
	September 30,		June 30,		September 30,	
	2017	2016	2017	2017	2016	2016
Cash flow from operating activities	\$124,000	\$125,480	\$ 87,601	\$ 296,580	\$ 284,324	
- Capital expenditures	8,515	11,590	9,377	28,054	28,642	
Free cash flow	\$115,485	\$113,890	\$ 78,224	\$ 268,526	\$ 255,682	

Conference Call to be Broadcast over the Internet

IDEX will broadcast its third quarter earnings conference call over the Internet on Tuesday, October 17, 2017 at 9:30 a.m. CT. Chairman and Chief Executive Officer Andy Silvernail and Senior Vice President and Chief Financial Officer William Grogan will discuss the Company's recent financial performance and respond to questions from the financial analyst community. IDEX invites interested investors to listen to the call and view the accompanying slide presentation, which will be carried live on its website at www.idexcorp.com. Those who wish to participate should log on several minutes before the discussion begins. After clicking on the presentation icon, investors should follow the instructions to ensure their systems are set up to hear the event and view the presentation slides, or download the correct applications at no charge. Investors will also be able to hear a replay of the call by dialing 877.660.6853 (or 201.612.7415 for international participants) using the ID #13652255.

Forward-Looking Statements

This news release contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. These statements may relate to, among other things, capital expenditures, acquisitions, cost reductions, cash flow, revenues, earnings, market conditions, global economies and operating improvements, and are indicated by words or phrases such as "anticipates," "estimates," "plans," "expects," "projects," "forecasts," "should," "could," "will," "management believes," "the Company believes," "the Company intends," and similar words or phrases. These statements are subject to inherent uncertainties and risks that could cause actual results to differ materially from those anticipated at the date of this news release. The risks and uncertainties include, but are not limited to, the following: economic and political consequences resulting from terrorist attacks and wars; levels of industrial activity and economic conditions in the U.S. and other countries around the world; pricing pressures and other competitive factors, and levels of capital spending in certain industries - all of which could have a material impact on order rates and IDEX's results, particularly in light of the low levels of order backlogs it typically maintains; its ability to make acquisitions and to integrate and operate acquired businesses on a profitable basis; the relationship of the U.S. dollar to other currencies and its impact on pricing and cost competitiveness; political and economic conditions in foreign countries in which the company operates; interest rates; capacity utilization and the effect this has on costs; labor markets; market conditions and material costs; and developments with respect to contingencies, such as litigation and environmental matters. Additional factors that could cause actual results to differ materially from those reflected in the forward-looking statements include, but are not limited to, the risks discussed in the "Risk Factors" section included in the Company's most recent annual report on Form 10-K filed with the SEC and the other risks discussed in the Company's filings with the SEC. The forward-looking statements included here are only made as of the date of this news release, and management undertakes no obligation to publicly update them to reflect subsequent events or circumstances, except as may be required by law. Investors are cautioned not to rely unduly on forward-looking statements when evaluating the information presented here.

About IDEX

IDEX Corporation is an applied solutions company specializing in fluid and metering technologies, health and science technologies, and fire, safety and other diversified products built to its customers' exacting specifications. Its products are sold in niche markets to a wide range of industries throughout the world. IDEX shares are traded on the New York Stock Exchange and Chicago Stock Exchange under the symbol "IEX".

For further information on IDEX Corporation and its business units, visit the company's website at www.idexcorp.com.

(Financial reports follow)

IDEX CORPORATION
Condensed Consolidated Statements of Operations
(in thousands except per share amounts)
(unaudited)

	Quarter Ended September 30,		Nine Months Ended September 30,	
	2017	2016 ^(e)	2017	2016 ^(e)
Net sales	\$ 574,490	\$ 530,356	\$ 1,701,408	\$ 1,582,624
Cost of sales	316,560	299,467	935,612	884,342
Gross profit	257,930	230,889	765,796	698,282
Selling, general and administrative expenses	131,426	119,114	393,691	369,339
Restructuring expenses	-	-	4,797	-
Loss (gain) on sale of businesses - net	-	2,067	-	2,067
Operating income	126,504	109,708	367,308	326,876
Other (income) expense - net	1,653	(1,513)	1,717	(2,496)
Interest expense	11,064	11,913	33,920	33,607
Income before income taxes	113,787	99,308	331,671	295,765
Provision for income taxes	30,019	29,435	88,160	82,003
Net income	\$ 83,768	\$ 69,873	\$ 243,511	\$ 213,762

Earnings per Common Share ^(a):

Basic earnings per common share	\$ 1.09	\$ 0.92	\$ 3.19	\$ 2.81
Diluted earnings per common share	\$ 1.08	\$ 0.91	\$ 3.15	\$ 2.78

Share Data:

Basic weighted average common shares outstanding	76,309	75,819	76,215	75,753
Diluted weighted average common shares outstanding	77,523	76,880	77,246	76,742

Condensed Consolidated Balance Sheets
(in thousands)
(unaudited)

September 30, December 31,
2017 2016

	September 30, 2017	December 31, 2016
Assets		
Current assets		
Cash and cash equivalents	\$ 303,291	\$ 235,964
Receivables - net	307,505	272,813
Inventories	266,705	252,859
Other current assets	77,977	61,085
Total current assets	955,478	822,721
Property, plant and equipment - net	250,889	247,816
Goodwill and intangible assets	2,094,621	2,068,096
Other noncurrent assets	16,773	16,311
Total assets	\$ 3,317,761	\$ 3,154,944
Liabilities and shareholders' equity		
Current liabilities		
Trade accounts payable	\$ 137,917	\$ 128,933
Accrued expenses	170,223	152,852
Short-term borrowings	347	1,046
Dividends payable	28,364	26,327
Total current liabilities	336,851	309,158
Long-term borrowings	874,853	1,014,235
Other noncurrent liabilities	295,745	287,657
Total liabilities	1,507,449	1,611,050
Shareholders' equity	1,810,312	1,543,894
Total liabilities and shareholders' equity	\$ 3,317,761	\$ 3,154,944

IDEX CORPORATION
Condensed Consolidated Statements of Cash Flows
(in thousands)
(unaudited)

	Nine Months Ended September 30,	
	2017	2016
Cash flows from operating activities		
Net income	\$ 243,511	\$ 213,762
Adjustments to reconcile net income to net cash provided by operating activities:		
Loss (gain) on sale of businesses - net	-	2,067
Depreciation and amortization	28,425	28,360
Amortization of intangible assets	35,381	35,964
Amortization of debt issuance costs	989	1,150
Share-based compensation expense	18,143	15,325
Deferred income taxes	1,888	4,880
Non-cash interest expense associated with forward starting swaps	5,004	5,144
Changes in (net of the effect from acquisitions and divestitures):		
Receivables	(28,407)	(2,178)
Inventories	(4,869)	22,250
Other current assets	(15,113)	(18,276)
Trade accounts payable	3,681	(16,696)
Accrued expenses	9,912	(2,982)
Other — net	(1,965)	(4,446)
Net cash flows provided by operating activities	296,580	284,324
Cash flows from investing activities		
Purchases of property, plant and equipment	(28,054)	(28,642)
Acquisition of businesses, net of cash acquired	-	(510,001)
Proceeds from sale of businesses, net of cash sold	-	32,529
Proceeds from fixed asset disposals	5,159	-
Other — net	(337)	(73)
Net cash flows used in investing activities	(23,232)	(506,187)
Cash flows from financing activities		
Borrowings under revolving facilities	33,000	460,524
Proceeds from 3.20% Senior Notes	-	100,000
Proceeds from 3.37% Senior Notes	-	100,000
Payments under revolving facilities	(181,692)	(402,172)
Debt issuance costs	-	(246)
Dividends paid	(82,869)	(77,367)
Proceeds from stock option exercises	18,980	23,154
Purchase of common stock	(22,650)	(57,272)
Unvested shares surrendered for tax withholding	(5,903)	(4,899)
Settlement of foreign exchange contracts	4,406	-
Net cash flows provided by (used in) financing activities	(236,728)	141,722
Effect of exchange rate changes on cash and cash equivalents	30,707	(8,480)
Net increase (decrease)	67,327	(88,621)
Cash and cash equivalents at beginning of year	235,964	328,018
Cash and cash equivalents at end of period	\$ 303,291	\$ 239,397

IDEX CORPORATION
Company and Segment Financial Information - Reported
(dollars in thousands)
(unaudited)

	Quarter Ended		Nine Months Ended	
	September 30, ^(b)		September 30, ^(b)	
	2017	2016 ^(e)	2017	2016 ^(e)
Fluid & Metering Technologies				
Net sales	\$ 220,953	\$ 208,335	\$ 658,905	\$ 641,988
Operating income ^(c)	61,988	55,907	179,830	161,782
Operating margin	28.1 %	26.8 %	27.3 %	25.2 %
EBITDA	\$ 67,950	\$ 62,904	\$ 196,946	\$ 183,227
EBITDA margin	30.8 %	30.2 %	29.9 %	28.5 %
Depreciation and amortization	\$ 6,192	\$ 7,168	\$ 17,823	\$ 22,011
Capital expenditures	3,944	5,091	12,159	12,704
Health & Science Technologies				
Net sales	\$ 207,127	\$ 183,564	\$ 611,215	\$ 556,475
Operating income ^(c)	46,073	37,195	134,605	118,985
Operating margin	22.2 %	20.3 %	22.0 %	21.4 %
EBITDA	\$ 58,232	\$ 48,742	\$ 168,955	\$ 153,577
EBITDA margin	28.1 %	26.6 %	27.6 %	27.6 %
Depreciation and amortization	\$ 11,189	\$ 11,163	\$ 34,447	\$ 33,044
Capital expenditures	3,015	4,450	11,489	11,455
Fire & Safety/Diversified Products				
Net sales	\$ 146,599	\$ 138,767	\$ 432,029	\$ 384,996
Operating income ^(c)	36,199	32,492	106,022	92,566
Operating margin	24.7 %	23.4 %	24.5 %	24.0 %
EBITDA	\$ 38,864	\$ 36,271	\$ 115,297	\$ 101,367
EBITDA margin	26.5 %	26.1 %	26.7 %	26.3 %
Depreciation and amortization	\$ 3,709	\$ 3,584	\$ 10,938	\$ 8,316
Capital expenditures	1,506	2,034	4,178	4,305
Corporate Office and Eliminations				
Intersegment sales eliminations	\$ (189)	\$ (310)	\$ (741)	\$ (835)
Operating loss ^(c)	(17,756)	(15,886)	(53,149)	(46,457)
EBITDA	(18,915)	(14,504)	(51,801)	(44,475)
Depreciation and amortization	190	277	598	953
Capital expenditures	50	15	228	178
Company				
Net sales	\$ 574,490	\$ 530,356	\$ 1,701,408	\$ 1,582,624
Operating income	126,504	109,708	367,308	326,876
Operating margin	22.0 %	20.7 %	21.6 %	20.7 %
EBITDA	\$ 146,131	\$ 133,413	\$ 429,397	\$ 393,696
EBITDA margin	25.4 %	25.2 %	25.2 %	24.9 %
Depreciation and amortization ^(d)	\$ 21,280	\$ 22,192	\$ 63,806	\$ 64,324
Capital expenditures	8,515	11,590	28,054	28,642

- (a) Calculated by applying the two-class method of allocating earnings to common stock and participating securities as required by ASC 260, Earnings Per Share.
- (b) Three and nine month data includes the results of SFC Koenig (September 2016) in the Health & Science Technologies segment and Akron Brass (March 2016) and AWG Fittings (July 2016) in the Fire & Safety/Diversified Products segment from the date of acquisition. Three and nine month data also includes the results of Hydra-Stop (July 2016) and IETG (October 2016) in the Fluid & Metering Technologies segment and CVI Japan (September 2016) and CVI Korea (December 2016) in the Health & Science Technologies segment through the date of disposition.
- (c) Segment operating income excludes unallocated corporate operating expenses which are included in Corporate Office and Eliminations.
- (d) Depreciation and amortization excludes amortization of debt issuance costs.
- (e) Certain amounts in the prior year presentation have been reclassified to conform to the current presentation due to the early adoption of ASU 2017-07, Compensation-Retirement Benefits (Topic 715): Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost.



Third Quarter 2017 Earnings

October 17, 2017

AGENDA

- **IDEX's Outlook**
- **Q3 2017 Financial Performance**
- **Q3 2017 Segment Performance**
 - Fluid & Metering
 - Health & Science
 - Fire & Safety / Diversified Products
- **2017 Guidance Detail**
- **Q&A**

Replay Information

- Dial toll-free: 877.660.6853
- International: 201.612.7415
- Conference ID: #13652255
- Log on to: www.idexcorp.com

Cautionary Statement Under the Private Securities Litigation Reform Act: Non-GAAP Measures


This presentation and discussion will include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. These statements may relate to, among other things, capital expenditures, acquisitions, cost reductions, cash flow, revenues, earnings, market conditions, global economies and operating improvements, and are indicated by words or phrases such as “anticipate,” “estimate,” “plans,” “expects,” “projects,” “forecasts,” “should,” “could,” “will,” “management believes,” “the company believes,” “the company intends,” and similar words or phrases. These statements are subject to inherent uncertainties and risks that could cause actual results to differ materially from those anticipated at the date of this news release. The risks and uncertainties include, but are not limited to, the following: economic and political consequences resulting from terrorist attacks and wars; levels of industrial activity and economic conditions in the U.S. and other countries around the world; pricing pressures and other competitive factors, and levels of capital spending in certain industries – all of which could have a material impact on order rates and IDEX’s results, particularly in light of the low levels of order backlogs it typically maintains; its ability to make acquisitions and to integrate and operate acquired businesses on a profitable basis; the relationship of the U.S. dollar to other currencies and its impact on pricing and cost competitiveness; political and economic conditions in foreign countries in which the company operates; interest rates; capacity utilization and the effect this has on costs; labor markets; market conditions and material costs; and developments with respect to contingencies, such as litigation and environmental matters. Additional factors that could cause actual results to differ materially from those reflected in the forward-looking statements include, but are not limited to, the risks discussed in the “Risk Factors” section included in the company’s most recent annual report on Form 10-K filed with the SEC and the other risks discussed in the company’s filings with the SEC. The forward-looking statements included in this presentation and discussion are only made as of today’s date, and management undertakes no obligation to publicly update them to reflect subsequent events or circumstances, except as may be required by law. Investors are cautioned not to rely unduly on forward-looking statements when evaluating the information in this presentation and discussion.

This presentation contains non-GAAP financial information. Reconciliations of non-GAAP measures are included either in this presentation or our earnings release for the three-month period ending September 30, 2017, which is available on our website.

IDEX Q3 Financial Performance

(Dollars in millions, excl. EPS)


Sales




Adjusted EPS*



Adjusted Operating Margin*



Free Cash Flow



*Q3 '16 adjusted for the net loss on divestitures (\$2.1M)

Organic Sales growth of 7 percent drove a 17 percent increase in EPS

Fluid & Metering Technologies

(Dollars in millions)


Orders



Sales



Operating Margin



Q3 Sales Mix:	Organic	7%
	Divestitures	-2%
	FX	<u>1%</u>
	Reported Sales	6%

Q3 Highlights:

- ❑ FMT organic sales increased for the third quarter in a row
- ❑ Consecutive quarters of double-digit organic growth in orders and sales within the Agriculture platform
- ❑ New product development drove growth within Water
- ❑ Industrials continue to rebound with continued optimism
- ❑ Mid Stream market within Energy showing signs of recovery

Organic orders up 6 percent and organic sales up 7 percent


Orders

Organic: 6% increase




Sales

Organic: 10% increase



Operating Margin

190 bps increase



Q3 Sales Mix:	Component	Percentage
	Organic	10%
	Acquisition/Divestitures	3%
	FX	0%
	Reported Sales	13%

Q3 Highlights:

- ❑ Scientific Fluidics market continues to outperform
- ❑ MPT platform benefitted from both large as well as mid-size orders during the quarter
- ❑ Double digit organic order and sales growth at the Sealing platform due to strength in the Semicon market
- ❑ SFC acquisition outperforming expectations

Organic orders up 6 percent and organic sales up 10 percent

Fire & Safety / Diversified Products

(Dollars in millions)

Orders

Organic: 10% increase




Sales

Organic: 4% increase



Operating Margin

130 bps increase



Q3 Sales Mix:	Component	Percentage
	Organic	4%
	Acquisitions	0%
	FX	2%
	Reported Sales	6%

Q3 Highlights:

- ❑ Strong rebound by Dispensing with a few large orders secured
- ❑ Strong quarter at Band-It, with market share gains in auto and a rebound in energy
- ❑ North American market remains solid within both Fire and Rescue
- ❑ Recent Fire acquisitions integrating well with legacy businesses

Organic orders up 10 percent and organic sales up 4 percent

Outlook: 2017 Guidance Summary

Q4 2017

- EPS estimate range: \$1.06 – \$1.08
- Organic revenue growth: ~ 6%
- Operating margin: ~ 22.0%
- Tax rate: ~ 28.5%
- FX impact: ~ 3.0% topline tailwind based on September 30, 2017 FX rates
- Corporate costs: ~ \$17 million

FY 2017

- Adjusted EPS estimate range: \$4.25 – \$4.27
- Organic revenue growth: ~ 5%
- Operating margin: ~ 22.0%
- FX impact: Flat based on September 30, 2017 FX rates
- Other modeling items
 - Tax rate: ~ 27%
 - Cap Ex: ~ \$40M
 - Free Cash Flow will be ~120% of net income
 - EPS estimate excludes all future acquisitions and associated costs and any future restructuring charges
 - Corporate costs ~ \$70 million

